Differentiated pharmacotherapy of generalized anxiety disorder

Abstract

This article discusses the possibility of a differentiated approach to the selection of medications for the treatment of generalized anxiety disorder (GAD), principles and approaches to therapy are
formulated that correspond to modern aspirations for personified medicine. In the existing recommendations for GAD therapy, the clinical features of the drugs are not taken into account and
the principle of compliance of the spectrum of psychotropic activity of the patient’s psychopathological structure chosen for therapy with the drug is not taken into account and is not observed.
Based on the literature data analysis, it is shown that the drugs used to treat GAD differ in the spectrum of their somatotropic and psychotropic effects. These spectra should be taken into
account in the initial choice of the drug and correspond to the somato:neurological status of the patient and the clinical features of the course of the disease. In particular, it has been shown
that with the prevalence of somatic anxiety in the patient’s status, prescribing pregabalin or short courses of benzodiazepine anxiolytics is advisable. Antidepressants are more indicated when
psychic anxiety predominates. Such patients can also be prescribed pregabalin.